Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Benza Block is a line of over-the-counter, designated Class 2 cold medicines marketed in Japan that combine the nonsteroidal anti-inflammatory drug ibuprofen with various antihistamines, sympathomimetic decongestants, antitussives, mucolytics, and ancillary agents to relieve multiple symptoms of the common cold, including fever, sore throat, nasal congestion, runny nose, cough, phlegm, headache, chills, and musculoskeletal pain. Different Benza Block variants (such as IP, L, L Premium, and YASUMO) adjust ingredient ratios and add components like tranexamic acid for mucosal inflammation, l-carbocysteine or guaifenesin for sputum, pseudoephedrine or dl-methylephedrine for nasal and bronchial symptoms, and first-generation antihistamines such as chlorpheniramine or diphenhydramine to control rhinorrhea and sneezing while, in some nighttime formulas, omitting caffeine to avoid insomnia.[1][2][3][4][6][7]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Benza Block.